Table 1 Characteristics of the participants

 Age (years), median (IQR)

45.6 (34.9–56.1)

54.3 (43.2–64.1)

61.2 (51.3–69.1)

57.9 (48.3–64.7)

50.5 (42.0–59.2)

45.7 (33.4–54.6)

43.0 (29.6–53.9)

 Female, n (%)

111 (83)

617 (56)

308 (76)

104 (53)

75 (38)

53 (43)

77 (40)

 Male, n (%)

23 (17)

491 (44)

95 (24)

91 (47)

120 (62)

71 (57)

114 (60)

 Patient reported disease activity, median (IQR)^ab

20 (10–40)

20 (10–41)

25 (11–40)

21 (10–40)

15 (5–35)

20 (10–30)

 BNT162b2 × 2

11 (8)

780 (70)

282 (70)

135 (69)

125 (64)

94 (76)

144 (75)

 mRNA-1273 × 2

43 (32)

285 (26)

108 (26.8)

52 (27)

60 (31)

25 (20)

40 (21)

 Mixed^c

80 (60)

37 (3)

12 (3)

7 (3.5)

10 (5)

3 (2.4)

5 (3)

 COVID-19 infection and one vaccine dose

0

6 (1)

1 (0.2)

1 (0.5)

0

2 (1.6)

2 (1)

 Rituximab

31 (3)

31 (8)

  - Monotherapy

464 (42)

51 (12.5)

60 (31)

163 (83.5)

67 (54)

123 (64)

  - Combination therapy^d

261 (23.5)

106 (26)

64 (32)

25 (13)

24 (19)

43 (23)

  - Tocilizumab

19 (2)

17 (4)

2 (1)

  - Other interleukin inhibitors^e

25 (2)

6 (3)

2 (1)

3 (2)

14 (7)

 Janus kinase inhibitors

22 (2)

13 (3)

2 (1)

6 (5)

1 (1)

 Abatacept

6 (0.5)

6 (1.5)

 Vedolizumab

32 (3)

22 (18)

10 (5)

  - Methotrexate monotherapy

218 (19.5)

161 (40)

53 (27)

4 (2)

  - Other metabolite inhibitors^f

17 (1.5)

11 (3)

4 (2)

2 (2)

 Prednisolone monotherapy

13 (1)

7 (2)

2 (3)

1 (0.5)